BIOSID support structure

A full and complementary management chain in direct relation with the European commission.

Management structure

Management structure

The management and coordination structure will be organized as follows:

The Project Coordinator (PC)

Photo Séverine Sigrist- DEFYMEDDr Séverine Sigrist from CeeD, represents the coordinating entity and have the contractual responsibility of the project, its overall management, organization and control. At the core of the project management, she liaises with the European Commission and acts as an interface between the EC services and consortium members. She is responsible for overseeing the implementation of the project’s analytical scheme, ensuring an effective overall administrative and financial management of the project, reporting to the EC, developing the dissemination strategy (together with the WP6 Leader) and ensuring smooth communication flows within the consortium.

The General Steering Committee (GSC)

The GSC is the decision-making body of the Consortium and is composed of representatives of the partners. It is assisted by the Technical and Managerial Support Team. The GSC is composed of:

The Technical and Managerial Support Team (TMST)

The advancement of work is supervised by a Technical and Managerial Support Team which will report work progress as well as any difficulty or delay to the GSC.

The TMST is composed of the Leaders of Work Packages 1 to 5, the Exploitation and IPR Manager and the WP6 Leader for dissemination:

For each work package, the WPL coordinates all the technical activities for that work package. When a work package is in progress, the leader will report to the GSC presenting progresses and related issues. Leaders are responsible for ensuring that deliverables are presented in due time. They coordinate the preparation the “Six-monthly progress reports” regarding their WP and coordinate as well the presentation of progress results in the biannual meetings. WPLs are the following: Dr. Elisa Maillard (from CeeD, for the WP1), Dr. Colin Wilde (from AvantiCell for WP2), Dr. Daniel Brandhorst (from NDS, for the WP3), Prof. Pierre Gianello (from UCL, for the WP4) and Prof. Eric Renard (from CHU, for the WP5).

Dr. Richard Bouaoun (DEFYMED) is responsible, under the supervision of the Technical and Managerial Support Team (TMST), of all the issues related to the exploitation and IPR and wide diffusion of the project results.

Dr. Richard Bouaoun (DEFYMED) is responsible, under the supervision of the Technical and Managerial Support Team (TMST), of all the issues related to the dissemination.

Ethics and Good Practice Committee (EGPC)

The EGPC gathers the Prof. Eric Renard (from CHU of Montpellier, for the human part) and Dr. Allan Langlois (From CeeD, for the animal part). The Ethics and Good Practice Committee provides updates and input to the management activity report.

The External Advisory Board (EAB)

The consortium consisting of a large number of partners and having a multi-disciplinary focus, the consortium thought relevant to include an EAB in the management plan. Therefore, the EAB gathers famous external advisers, namely:

Thierry BerneyThierry Berney, MD, MSc is a Professor of Surgery at the University of Geneva School of Medicine and an attending surgeon in the Division of Visceral and Transplantation Surgery at Geneva University Hospitals. He graduated from the University of Geneva School of Medicine in 1987 and specialized in Visceral Surgery in Switzerland. He further specialized in Transplantation Surgery in Brussels, Belgium and Miami, Florida, with a particular interest in islet, pancreas and small bowel transplantation. Since 2002, he is an attending surgeon  in Visceral Surgery, with a focus on Pancreatic and Gastro-Intestinal Surgery. He is the head of the Cell Isolation and Transplantation Center, and the director of the Islet and Pancreas Transplant Programs in Geneva University Hospitals, which is one of the most active worldwide. He is a founding member of the Intestinal Transplant Association, and a member of several Surgical and Transplantation Societies.  From 2005 to 2011, he has been a Councilor of the International Pancreas and Islet Transplantation  Association (IPITA), and serves as Treasurer of IPITA since 2011.  From 2007 to 2013, he has been the founding Chairman of the European Pancreas and Islet Transplantation  Association (EPITA). He currently serves as Secetary of the European Society for Organ Transplantation (ESOT) and is the President-elect of the Swiss Society of Transplantation. He is the author of more than 200 articles and book chapters.

Henquin 09bJean-Claude Henquin, MD, PHD graduated from the University of Louvain, Belgium. He then became Research Director of the Foundation for Scientific Research and developed his own research group in his Alma Mater.  In 1992, he was appointed Full Professor of human Physiology and head of the unit of Endocrinology and Metabolism at the Medical Faculty of the University of Louvain, in Brussels, where he remains active since he became emeritus in 2011. His research, focused on the composition of the islets of Langerhans and on the control of insulin secretion, has made him a recognized expert in the pathophysiology of the endocrine pancreas and was recognized by several belgian and international awards.  He is also a member of the Royal Academy of Medicine of Belgium and of the Academia Europaea.


Bernhard HeringBernhard Hering, MD is a Professor of Surgery and Medicine at the University of Minnesota, Minneapolis,  scientific director of the Schulze Diabetes Institute, department of surgery at the University of Minnesota, Director of Islet Research and Transplantation Program at the University of Minnesota. Professor Hering is internationally renowned for his expertise in islet cell transplantation. His research focuses on finding innovative cell-based therapies to restore blood glucose control and insulin independence for people with type 1 diabetes. Additionally, he is committed to exploring new sources of islet cells through xenotransplantation. He is the medical director of the Collaborative Islet Transplant Registry (CITR), and has also served as president of the Cell Transplant Society and as councilor of the International Pancreas and Islet Transplant Association. He also serves on steering committees of major clinical research programs in transplantation and diabetes such as the National Institutes of Health (NIH) Immune Tolerance Network, the Type 1 Diabetes TrialNet, and the Clinical Islet Transplant Consortium, which is the largest ever funded research activity in islet transplantation.

Joao NabaisJoão Manuel Valente Nabais, PhD in Chemistry from the University of Evora (Portugal). He is President of the International Diabetes Federation Europe (IDF Europe). Since 2002, he works as Assistant Professor at the University of Evora. Diagnosed with type 1 diabetes in 1981, João has been actively involved in the field of diabetes ever since his youth through participation and support in numerous activities of APDP – the Portuguese Diabetes Association. He is himself the founder of two local diabetes associations and the President of one of them, the Evora Diabetes Association. At national level, João has served for 10 years as Board Member of APDP, sitting on the association’s Ethical Committee and working on different projects including youth camps, advocating for the Declaration of the European Parliament on diabetes and supporting the Unite for diabetes campaign. From 2008 to 2011, he also served as President of APDP’s Ethical Committee. Furthermore, his work for APDP includes close collaboration on the educational courses provided to people with diabetes and parents of children with diabetes. Additionally, João Nabais played an important role in the campaign for the reimbursement of test-strips in Portugal.


Overall management structure

Overall management structure